RAP charting, page-83

It's likely that the trial results will keep strengthening with each enrolled patient - I wonder if the USA advisors will recommend an FDA submission for sign off on a paediatric specific app? After all the company seems to have no further paediatric trials planned and should be at the point where the data is sufficient early in the new year. Obviously a smaller market, but is there any downside to getting out there in a limited capacity ahead of the adult studies? It would certainly give a different complexion to the company and their prospects if they already had one version being commercialised ahead of the main event.